Mirogabalin as a Novel Gabapentinoid for the Treatment of Chronic Pain Conditions: An Analysis of Current Evidence (Review Article)

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

Chen Eric Y.; Beutler Sascha S.; Kaye Alan D.; Edinoﬀ Amber N.; KHADEMI SEYED HOSSEIN; Stoltz Andrea E.; Rueb Nicole R.; Cornett Elyse M.; Suh Winston J.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Anesthesiology and Pain Medicine Year:2021 | Volume:11 | Issue:6 Page(s): 0-0

Download Full-Text

View:

Download:

Cites:

Information Journal Paper

Title

Mirogabalin as a Novel Gabapentinoid for the Treatment of Chronic Pain Conditions: An Analysis of Current Evidence (Review Article)

Author(s)

Keywords

Mirogabalin

Gabapentinoid

Diabetic Peripheral Neuropathic Pain

Postherpetic Neuralgia

Fibromyalgia

Anxiety

Abstract

Neuropathic pain is a challenge for physicians to treat and often requires a multimodal approach with both pharmacologic and lifestyle interventions. Mirogabalin, a potent, selective ligand of the 2-1 and 2-2 subunits of voltage-gated calcium channels (VGCCs), provides analgesia by inhibiting neurotransmitter release at the presynaptic end of the neuron. Mirogabalin oﬀ ers more sustained analgesia than its Gabapentinoid counterparts in addition to a wider safety margin for adverse events. Recent clinical trials of Mirogabalin have demonstrated both eﬃ cacy and tolerability of the drug for the treatment of Diabetic Peripheral Neuropathic Pain and Postherpetic Neuralgia, leading to its approval in Japan. While still not yet FDA approved, Mirogabalin is still in its infancy and oﬀ ers potential into the treatment of neuropathic pain and its associated comorbidities.

Cites

No record.

References

No record.

Cite

APA: Copy

Chen, Eric Y., Beutler, Sascha S., Kaye, Alan D., Edinoﬀ, Amber N., KHADEMI, SEYED HOSSEIN, Stoltz, Andrea E., Rueb, Nicole R., Cornett, Elyse M., & Suh, Winston J.. (2021). Mirogabalin as a Novel Gabapentinoid for the Treatment of Chronic Pain Conditions: An Analysis of Current Evidence (Review Article). ANESTHESIOLOGY AND PAIN MEDICINE, 11(6), 0-0. SID. https://sid.ir/paper/975691/en

Vancouver: Copy

Chen Eric Y., Beutler Sascha S., Kaye Alan D., Edinoﬀ Amber N., KHADEMI SEYED HOSSEIN, Stoltz Andrea E., Rueb Nicole R., Cornett Elyse M., Suh Winston J.. Mirogabalin as a Novel Gabapentinoid for the Treatment of Chronic Pain Conditions: An Analysis of Current Evidence (Review Article). ANESTHESIOLOGY AND PAIN MEDICINE[Internet]. 2021;11(6):0-0. Available from: https://sid.ir/paper/975691/en

IEEE: Copy

Eric Y. Chen, Sascha S. Beutler, Alan D. Kaye, Amber N. Edinoﬀ, SEYED HOSSEIN KHADEMI, Andrea E. Stoltz, Nicole R. Rueb, Elyse M. Cornett, and Winston J. Suh, “Mirogabalin as a Novel Gabapentinoid for the Treatment of Chronic Pain Conditions: An Analysis of Current Evidence (Review Article),” ANESTHESIOLOGY AND PAIN MEDICINE, vol. 11, no. 6, pp. 0–0, 2021, [Online]. Available: https://sid.ir/paper/975691/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops